Humatica advises the Riverside Company on their recent investment in Alter Pharma

ndetails

Humatica Ltd. was retained to advise the Riverside Company on its investment in Alter Pharma, a Belgian pharmaceutical group. Alter Pharma distributes EU-sourced pharmaceutical products to wholesalers pharmacies and hospitals. It also develops and reformulates generic pharmaceuticals using GMP approved third-party manufacturers, and sells them internationally through partnerships

Humatica provided organisational due diligence services for this transaction.

To view press release: Humatica Advisor to Riverside for AlterPharma

Related News

Humatica announces senior promotions in London and Zurich
01 Apr., 2026 By Humatica

Humatica announces senior promotions in London and Zurich

Humatica is pleased to announce two senior level promotions, reflecting continued growth and the strengthening of its leadership team. Paul Simpson, based in Zurich, has…

Read more arrowicon
Humatica once again recognised as a leader in private equity value creation by Actum in its 2026 awards
27 Jan., 2026 By Humatica

Humatica once again recognised as a leader in private equity value creation by Actum in its 2026 awards

Humatica has once again been short-listed for Actum’s 2026 Value Creation Award in the People & Organisational Strategy category. This recognition reflects Humatica’s 23‑year commitment…

Read more arrowicon
Humatica is again finalist for prestigious Real Deals Award
16 Jan., 2026 By Humatica

Humatica is again finalist for prestigious Real Deals Award

Humatica is once again shortlisted for Real Deals’ prestigious Private Equity Awards 2026 in the “Value Creation Adviser of the Year” category. This recognition underscores…

Read more arrowicon